Note 11 - Business Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Revenue
ONM Environmental	$	776		$	3,853		$	5,583		$	12,437
BLEST		450			824			2,080			2,439
BioLargo Canada		37			—			46			—
Intersegment revenue		(160	)		(326	)		(561	)		(754	)
Total	$	1,103		$	4,351		$	7,148		$	14,122
Stock option expense
BioLargo corporate	$	(651	)	$	(194	)	$	(1,352	)	$	(1,099	)
Clyra Medical		(193	)		(43	)		(599	)		(165	)
Total	$	(844	)	$	(237	)	$	(1,951	)	$	(1,264	)
Depreciation expense
BioLargo corporate	$	(9	)	$	(9	)	$	(28	)	$	(28	)
ONM Environmental		(11	)		(10	)		(34	)		(27	)
BLEST		(9	)		(17	)		(37	)		(53	)
Clyra Medical		(3	)		(3	)		(7	)		(7	)
BETI		(2	)		—			(6	)		—
Total	$	(34	)	$	(39	)	$	(112	)	$	(115	)
Research and development expense
BioLargo corporate	$	(175	)	$	(301	)	$	(642	)	$	(838	)
BLEST		(222	)		(157	)		(541	)		(845	)
BETI		(47	)		(133	)		(161	)		(346	)
BioLargo Canada		(100	)		(134	)		(356	)		(311	)
Clyra Medical		(231	)		(291	)		(795	)		(512	)
Intersegment R&D		160			326			561			754
Total	$	(615	)	$	(690	)	$	(1,934	)	$	(2,098	)
Operating income (loss)
BioLargo corporate	$	(1,172	)	$	(798	)	$	(3,034	)	$	(3,165	)
ONM Environmental		(3,807	)		1,382			(2,026	)		4,668
BLEST		(403	)		(375	)		(763	)		(1,067	)
BETI		(128	)		(194	)		(346	)		(575	)
BEST		(83	)		(59	)		(208	)		(174	)
BioLargo Canada		(104	)		(160	)		(404	)		(383	)
Clyra Medical		(1,483	)		(857	)		(4,063	)		(2,019	)
Total	$	(7,180	)	$	(1,061	)	$	(10,844	)	$	(2,715	)
Interest income (expense)
BioLargo corporate	$	(5	)	$	(3	)	$	(14	)	$	(6	)
ONM Environmental		(1	)		—			(4	)		(4	)
BLEST		—			—			—			—
Clyra Medical		(138	)		(9	)		(334	)		(22	)
Total	$	(144	)	$	(12	)	$	(352	)	$	(32	)

As of September 30, 2025	BioLargo		ONM		BLEST		CLYRA		BETI		BEST		BioLargo Canada		Elimination			Total
Tangible assets	$	678	$	2,565	$	850	$	3,659	$	87	$	—	$	1	$	(203	)	$	7,637
Operating lease right-of use		268		—		627		175		—		—		—		—			1,070
Finance lease right-of-use		—		—		—		400		—		—		—		—			400
Investment in South Korean joint venture		23		—		—		—		—		—		—		—			23
Total	$	969	$	2,565	$	1,477	$	4,234	$	87	$	—	$	1	$	(203	)	$	9,130

As of December 31, 2024	BioLargo		ONM		BLEST		CLYRA		BETI		BEST		BioLargo Canada		Elimination			Total
Tangible assets	$	775	$	5,879	$	790	$	1,696	$	46	$	—	$	104	$	(234	)	$	9,056
Operating lease right-of use		333		—		659		—		—		—		—		—			992
Finance lease right-of-use		—		—		—		451		—		—		—		—			451
Investment in South Korean joint venture		14		—		—		—		—		—		—		—			14
Total	$	1,122	$	5,879	$	1,449	$	2,147	$	46	$	—	$	104	$	(234	)	$	10,513